Stay updated with breaking news from Start Codon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a £2.14 million s
Investors include Parkwalk Advisors, University of Cambridge Seed Funds, Martlet Capital, and angel investors.
Funding will support recruitment, commercial partnerships, and further development of Semarion's SemaCyte cell assaying platform, which turns adherent cells into liquid reagents to enable novel
Venture capital funding broke records in the biotech industry in 2021. Leading startup incubators from across Europe share their plans to make the most of this trend in 2022, with expectations for big returns and expansion in the works.
Share this article Share this article MOTHERWELL, Scotland, May 6, 2021 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. Although already over-subscribed, the company's Series A remains open to ot...